CA2469045A1 - Methods of therapy for non-hodgkin's lymphoma - Google Patents
Methods of therapy for non-hodgkin's lymphoma Download PDFInfo
- Publication number
- CA2469045A1 CA2469045A1 CA002469045A CA2469045A CA2469045A1 CA 2469045 A1 CA2469045 A1 CA 2469045A1 CA 002469045 A CA002469045 A CA 002469045A CA 2469045 A CA2469045 A CA 2469045A CA 2469045 A1 CA2469045 A1 CA 2469045A1
- Authority
- CA
- Canada
- Prior art keywords
- dose
- administered
- antibody
- week
- total weekly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1796801A | 2001-12-07 | 2001-12-07 | |
US10/017,968 | 2001-12-07 | ||
US10/293,664 US20030185796A1 (en) | 2000-03-24 | 2002-11-12 | Methods of therapy for non-hodgkin's lymphoma |
US10/293,664 | 2002-11-12 | ||
PCT/US2002/039253 WO2003049694A2 (en) | 2001-12-07 | 2002-12-06 | Methods of therapy for non-hodgkin's lymphoma |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2469045A1 true CA2469045A1 (en) | 2003-06-19 |
Family
ID=26690566
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002469045A Abandoned CA2469045A1 (en) | 2001-12-07 | 2002-12-06 | Methods of therapy for non-hodgkin's lymphoma |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1463524A4 (ja) |
JP (1) | JP2005538034A (ja) |
AU (1) | AU2002362098A1 (ja) |
CA (1) | CA2469045A1 (ja) |
WO (1) | WO2003049694A2 (ja) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0316779B1 (pt) | 2002-12-16 | 2020-04-28 | Genentech Inc | anticorpo humanizado que liga cd20 humano, composição, artigo manufaturado, método de indução da apoptose, método de tratamento de câncer cd20 positivo, métodos de tratamento de doenças autoimunes, ácidos nucléicos isolados, vetores de expressão, células hospedeiras, método para a produção de um anticorpo 2h7 humanizado, polipeptídeo isolado, formulação líquida, método de tratamento de artrite reumatóide (ra) e anticorpos de ligação de cd20 humanizados |
ES2538469T3 (es) | 2003-06-05 | 2015-06-22 | Genentech, Inc. | Terapia de combinación para trastornos de células B |
US8147832B2 (en) * | 2003-08-14 | 2012-04-03 | Merck Patent Gmbh | CD20-binding polypeptide compositions and methods |
WO2005062929A2 (en) * | 2003-12-22 | 2005-07-14 | Chiron Coporation | Use of fc receptor polymorphisms as diagnostics for treatment strategies for immune-response disorders |
US20050265966A1 (en) | 2004-05-20 | 2005-12-01 | Kindsvogel Wayne R | Methods of treating cancer using IL-21 and monoclonal antibody therapy |
EP3130349A1 (en) | 2004-06-04 | 2017-02-15 | Genentech, Inc. | Method for treating multiple sclerosis |
EP1848454A1 (en) * | 2005-02-15 | 2007-10-31 | Novartis Vaccines and Diagnostics, Inc. | Methods for treating lymphomas using a combination of a chemotherapeutic agent and il-2 and optionally an anti-cd20 antibody |
MY149159A (en) | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
AU2006318539B2 (en) | 2005-11-23 | 2012-09-13 | Genentech, Inc. | Methods and compositions related to B cell assays |
DE17196350T1 (de) | 2007-07-09 | 2018-12-27 | Genentech, Inc. | Verhindern der disulfid-bindungsreduktion während der rekombinanten herstellung von polypeptiden |
EP2200631A1 (en) | 2007-10-16 | 2010-06-30 | Zymogenetics, Inc. | Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease |
US7914785B2 (en) | 2008-01-02 | 2011-03-29 | Bergen Teknologieverforing As | B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome |
EP2077281A1 (en) | 2008-01-02 | 2009-07-08 | Bergen Teknologioverforing AS | Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome |
ATE548052T1 (de) * | 2008-01-17 | 2012-03-15 | Philogen Spa | Kombination aus einem anti-edb-fibronectin- antikörper-il-2-fusionsprotein und einem b-zellen bindenden molekül, b-zellen-vorläufern und/oder deren krebserregendem gegenspieler |
TW201014605A (en) | 2008-09-16 | 2010-04-16 | Genentech Inc | Methods for treating progressive multiple sclerosis |
WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
KR20180114966A (ko) | 2009-08-11 | 2018-10-19 | 제넨테크, 인크. | 글루타민-비함유 세포 배양 배지에서의 단백질의 생성 |
CN102933231B (zh) | 2010-02-10 | 2015-07-29 | 伊缪诺金公司 | Cd20抗体及其用途 |
CA2985718A1 (en) | 2015-06-24 | 2016-12-29 | F. Hoffmann-La Roche Ag | Anti-transferrin receptor antibodies with tailored affinity |
PE20231655A1 (es) | 2015-10-02 | 2023-10-17 | Hoffmann La Roche | Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso |
CN115369086B (zh) * | 2022-02-22 | 2023-05-12 | 北京景达生物科技有限公司 | 一种nk细胞扩大培养的培养方案 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003528155A (ja) * | 2000-03-24 | 2003-09-24 | カイロン コーポレイション | Cd20に対する抗体とインターロイキン−2との組み合わせを用いる非ホジキンリンパ腫の治療方法 |
-
2002
- 2002-12-06 WO PCT/US2002/039253 patent/WO2003049694A2/en active Application Filing
- 2002-12-06 EP EP02797231A patent/EP1463524A4/en not_active Withdrawn
- 2002-12-06 CA CA002469045A patent/CA2469045A1/en not_active Abandoned
- 2002-12-06 JP JP2003550745A patent/JP2005538034A/ja not_active Withdrawn
- 2002-12-06 AU AU2002362098A patent/AU2002362098A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2002362098A1 (en) | 2003-06-23 |
EP1463524A2 (en) | 2004-10-06 |
WO2003049694A3 (en) | 2003-11-06 |
WO2003049694A2 (en) | 2003-06-19 |
AU2002362098A8 (en) | 2003-06-23 |
EP1463524A4 (en) | 2005-02-09 |
JP2005538034A (ja) | 2005-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20030185796A1 (en) | Methods of therapy for non-hodgkin's lymphoma | |
US20020009427A1 (en) | Methods of therapy for non-hodgkin's lymphoma | |
CA2469045A1 (en) | Methods of therapy for non-hodgkin's lymphoma | |
US7306801B2 (en) | Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein | |
JP6253842B2 (ja) | 抗cd20抗体の投与を含むb細胞リンパ腫の併用療法 | |
US20060251617A1 (en) | Methods for treating lymphomas | |
US20030235556A1 (en) | Combination IL-2/anti-HER2 antibody therapy for cancers characterized by overexpression of the HER2 receptor protein | |
US20070274948A1 (en) | Methods of Therapy for Chronic Lymphocytic Leukemia | |
EP1935431A2 (en) | Cancer treatments by using a combination of an antibody against her2 and interleukin-2 | |
JP2022549495A (ja) | 造血器がんの治療のための抗cd30 adc、抗pd-1、および化学療法剤の併用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |